Dementia is challenging to clinically diagnose with a wrong diagnosis given to 30% of persons presenting with cognitive complaints. Amyloid PET brain imaging is a valuable diagnostic tool for preclinical intervention, improved subject selection for therapeutic trials and measuring the effectiveness of anti-amyloid agents. In Part 2 of this series, Professor Chris Rowe, Director of the Australian Dementia Network, walks through some reading tests of amyloid PET brain imaging and the correct interpretations.

свернуть